HTN 80 mg once daily, can be increased to 160 mg. Heart failure 40 mg twice daily. Titration of doses to 80 mg & 160 mg twice daily. Post MI 12 hr after MI. Initial dose of 20 mg twice daily, titrated to 40 mg, 80 mg & 160 mg twice daily for the next few wk.
Treat conditions for Na deficiency &/or body fluids before starting treatment. Monitor serum creatinine or BUN in patients w/ bilateral or unilateral renal artery stenosis. Severe kidney
function impairment. Liver disorders. May impair ability to drive or operate machinery. Not recommended in breastfeeding.
Decrease in the amount of Hb & hematocrit, neutropenia & thrombocytopenia. Hypersensitivity & serum disorders. Increase in serum K levels. Vertigo. Vasculitis. Cough. Abdominal pain. Increase in liver action including increase in serum bilirubin. Angioedema, dermatitis bullous, rash, pruritus. Myalgia. Kidney disorders, increase in serum creatinine levels, increase in BUN level. Fatigue. Arthralgia, asthenia, back pain, dizziness, headache, insomnia, decreased libido, nausea, edema, pharyngitis, rhinitis, sinusitis, URTIs, viral infections.
Drug Interactions
Concurrent K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements or substitutes can increase serum K. Attenuation from HTN can occur w/ NSAIDs including selective COX-2 inhibitors. In elderly patients, vol-depleted, or patients who have abnormalities in kidney function, concomitant use w/ AIIA & NSAIDs can increase the risk of kidney damage.
Sign Out
